Physician profile
Jayashree Sinha
NPI 1780628495
$6,542.01
in general payments reported to CMS, 2019-2025
26 companies · $837 in 2025
The $837 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $1,022 · 2021: $1,112 · 2022: $1,142 · 2023: $787 · 2024: $910 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,526 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,526.10 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,493.04 | 2019-2025 | Rinvoq, Humira |
| Amgen INC. | $840.03 | 2019-2025 | Enbrel, Otezla, Evenity |
| Ucb, INC. | $545.93 | 2019-2025 | Bimzelx, Cimzia |
| Ani Pharmaceuticals, INC. | $459.36 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $415.70 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $282.63 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $219.13 | 2019-2022 | |
| Lilly USA, LLC | $209.48 | 2019-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $149.42 | 2019-2022 | |
| Genzyme Corporation | $144.44 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $144.39 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals Lp | $82.25 | 2021-2024 | Saphnelo |
| Horizon Therapeutics Plc | $74.85 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $74.70 | 2020 | |
| Genentech USA, INC. | $74.24 | 2019-2024 | Actemra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $67.80 | 2022-2024 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $64.04 | 2023-2024 | Idacio |
| Glaxosmithkline, LLC. | $38.80 | 2022-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $32.03 | 2021-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.76 | 2021 | |
| Sandoz INC. | $25.08 | 2023 | Hyrimoz |
| Mallinckrodt Enterprises LLC | $22.43 | 2019 | |
| Celgene Corporation | $14.83 | 2019 | |
| Merck Sharp & Dohme LLC | $13.80 | 2020 | |
| Astellas Pharma US INC | $13.71 | 2020 | |
| Pacira Therapeutics, INC. | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayashree Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.